Resalis Therapeutics, a Torino, Italy-based ncRNAs and RNA-targeted therapeutics company, raised €10M in Series A funding.
The round was led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors. In conjunction with the financing, Claus Andersson, PhD, General Partner of Sunstone Life Science Ventures, will join Resalis’ Board of Directors.
The company intends to use the funds to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program, RES-010, in obesity.
Led by CEO Alessandro Toniolo, Resalis Therapeutics provides a metabolic disease approach that targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on a preclinical evidence, Resalis will bring RES-010 into clinical trials for a range of metabolic disorders.
The company plans to initiate a Phase 1 clinical study evaluating the safety and efficacy of RES-010 in the first half of 2024. RES-010 is patent-protected in the US, Japan and China with patents pending in the EU.
FinSMEs
05/01/2024